Copyright © 2011 Nikhil Nihalani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. D. B. Allison, J. L. Mentore, M. Heo et al., “Antipsychotic-induced weight gain: a comprehensive research synthesis,” American Journal of Psychiatry, vol. 156, no. 11, pp. 1686–1696, 1999. View at Scopus
2. P. S. Masand, “Weight gain associated with psychotropic drugs,” Expert Opinion on Pharmacotherapy, vol. 1, no. 3, pp. 377–389, 2000. View at Scopus
3. H. Pijl and A. E. Meinders, “Bodyweight change as an adverse effect of drug treatment: mechanisms and management,” Drug Safety, vol. 14, no. 5, pp. 329–342, 1996. View at Scopus
4. H. Nasrallah, “A review of the effect of atypical antipsychotics on weight,” Psychoneuroendocrinology, vol. 28, no. 1, pp. 83–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
5. M. Fava, “Weight gain and antidepressants,” Journal of Clinical Psychiatry, vol. 61, no. 11, pp. 37–41, 2000. View at Scopus
6. C. L. Carman, N. M. Leung, and A. H. Gnberman, “Weight gain in epileptic patients during treatment with valproic acid: a retrospective study,” Canadian Journal of Neurological Sciences, vol. 24, no. 3, pp. 240–244, 1997.
7. T. G. Cantu and J. S. Korek, “Monoamine oxidase inhibitors and weight gain,” Drug Intelligence and Clinical Pharmacy, vol. 22, no. 10, pp. 755–759, 1988. View at Scopus
8. R. H. Weisler, J. A. Johnston, C. G. Lineberry, B. Samara, R. J. Branconnier, and A. A. Billow, “Comparison of bupropion and trazodone for the treatment of major depression,” Journal of Clinical Psychopharmacology, vol. 14, no. 3, pp. 170–179, 1994. View at Scopus
9. K. N. Roy Chengappa, J. Levine, D. Rathore, H. Parepally, and R. Atzert, “Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series,” European Psychiatry, vol. 16, no. 3, pp. 186–190, 2001. View at Publisher · View at Google Scholar · View at Scopus
10. T. Wetterling, “Bodyweight gain with atypical antipsychotics: a comparative review,” Drug Safety, vol. 24, no. 1, pp. 59–73, 2001. View at Scopus
11. R. S. McIntyre, M. Cohen, J. Zhao, L. Alphs, T. A. Macek, and J. Panagides, “Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial,” Journal of Affective Disorders, vol. 122, no. 1-2, pp. 27–38, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. D. Bishara and D. Taylor, “Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder,” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 483–490, 2009. View at Scopus
13. R. S. McIntyre, M. Cohen, J. Zhao, L. Alphs, T. A. Macek, and J. Panagides, “Asenapine versus olanzapine in acute mania: a double-blind extension study,” Bipolar Disorders, vol. 11, no. 8, pp. 815–826, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. P. J. Weiden, A. J. Cutler, M. H. Polymeropoulos, and C. D. Wolfgang, “Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials,” Journal of Clinical Psychopharmacology, vol. 28, no. 7, pp. S12–S19, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. E. Spina and R. Cavallaro, “The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia,” Expert Opinion on Drug Safety, vol. 6, no. 6, pp. 651–662, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. H. Y. Meltzer, W. V. Bobo, I. F. Nuamah et al., “Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies,” Journal of Clinical Psychiatry, vol. 69, no. 5, pp. 817–829, 2008. View at Scopus
17. S. Cohen, R. Glazewski, S. Khan, and A. Khan, “Weight gain with risperidone among patients with mental retardation: effect of calorie restriction,” Journal of Clinical Psychiatry, vol. 62, no. 2, pp. 114–116, 2001. View at Scopus
18. J. M. Russell and J. A. Mackell, “Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications,” CNS Drugs, vol. 15, no. 7, pp. 537–551, 2001. View at Scopus
19. R. Ganguli, J. S. Brar, and Z. Ayrton, “Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone,” Schizophrenia Research, vol. 49, no. 3, pp. 261–267, 2001. View at Publisher · View at Google Scholar · View at Scopus
20. Y. Barak, “No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment,” Journal of Clinical Psychiatry, vol. 63, no. 2, pp. 117–119, 2002. View at Scopus
21. D. M. Taylor and R. McAskill, “Atypical antipsychotics and weight gain—a systematic review,” Acta Psychiatrica Scandinavica, vol. 101, no. 6, pp. 416–432, 2000. View at Publisher · View at Google Scholar · View at Scopus
22. Y. Vanina, A. Podolskaya, K. Sedky et al., “Body weight changes associated with psycopharmacology,” Psychiatric Services, vol. 53, no. 7, pp. 842–847, 2002. View at Publisher · View at Google Scholar · View at Scopus
23. S. J. Kingsbury, M. Fayek, D. Trufasiu, J. Zada, and G. M. Simpson, “The apparent effects of ziprasidone on plasma lipids and glucose,” Journal of Clinical Psychiatry, vol. 62, no. 5, pp. 347–349, 2001.
24. P. E. Keck, M. Versiani, S. Potkin, S. A. West, E. Giller, and K. Ice, “Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial,” American Journal of Psychiatry, vol. 160, no. 4, pp. 741–748, 2003. View at Publisher · View at Google Scholar · View at Scopus
25. S. Cohen, B. Fitzgerald, A. Okos, S. Khan, and A. Khan, “Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation,” Journal of Clinical Psychiatry, vol. 64, no. 1, pp. 60–62, 2003. View at Scopus
26. M. Arato, R. O'Connor, and H. Y. Meltzer, “A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study,” International Clinical Psychopharmacology, vol. 17, no. 5, pp. 207–215, 2002. View at Scopus
27. J. A. Frazier, J. Biederman, M. Tohen et al., “A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder,” Journal of Child and Adolescent Psychopharmacology, vol. 11, no. 3, pp. 239–250, 2001.
28. K. H. Littrell, R. G. Petty, N. M. Hilligoss, C. D. Peabody, and C. G. Johnson, “Weight loss associated with olanzapine treatment,” Journal of Clinical Psychopharmacology, vol. 22, no. 4, pp. 436–437, 2002. View at Publisher · View at Google Scholar · View at Scopus
29. B. Søholm and H. Lublin, “Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study,” Acta Psychiatrica Scandinavica, vol. 107, no. 5, pp. 344–350, 2003. View at Publisher · View at Google Scholar · View at Scopus
30. J. A. Lieberman, G. Tollefson, M. Tohen et al., “Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol,” American Journal of Psychiatry, vol. 160, no. 8, pp. 1396–1404, 2003. View at Publisher · View at Google Scholar · View at Scopus
31. G. Ratzoni, D. Gothelf, A. Brand-Gothelf et al., “Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 41, no. 3, pp. 337–343, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. D. Gothelf, B. Falk, P. Singer et al., “Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine,” American Journal of Psychiatry, vol. 159, no. 6, pp. 1055–1057, 2002. View at Publisher · View at Google Scholar · View at Scopus
33. J. A. Shaw, J. E. Lewis, S. Pascal et al., “A study of quetiapine: efficacy and tolerability in psychotic adolescents,” Journal of Child and Adolescent Psychopharmacology, vol. 11, no. 4, pp. 415–424, 2001. View at Scopus
34. M. Brecher, I. W. Rak, K. Melvin, and A. M. Jones, “The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia,” International Journal of Psychiatry in Clinical Practice, vol. 4, no. 4, pp. 287–291, 2000. View at Publisher · View at Google Scholar · View at Scopus
35. D. Briffa and T. Meehan, “Weight changes during clozapine treatment,” Australian and New Zealand Journal of Psychiatry, vol. 32, no. 5, pp. 718–721, 1998. View at Scopus
36. C. J. Hong, C. H. Lin, W. Y. Yu Younger, K. H. Yang, and S. J. Tsai, “Genetic variants of the serotonin system and weight change during clozapine treatment,” Pharmacogenetics, vol. 11, no. 3, pp. 265–268, 2001. View at Publisher · View at Google Scholar · View at Scopus
37. G. Masi, M. Mucci, and S. Millepiedi, “Clozapine in adolescent inpatients with acute mania,” Journal of Child and Adolescent Psychopharmacology, vol. 12, no. 2, pp. 93–99, 2002. View at Scopus
38. D. B. Allison, J. L. Mentore, M. Heo et al., “Antipsychotic-induced weight gain: a comprehensive research synthesis,” American Journal of Psychiatry, vol. 156, no. 11, pp. 1686–1696, 1999. View at Scopus
39. J. S. Lamberti, T. Bellnier, and S. B. Schwarzkopf, “Weight gain among schizophrenic patients treated with clozapine,” American Journal of Psychiatry, vol. 149, no. 5, pp. 689–690, 1992. View at Scopus
40. S. G. Potkin, A. R. Saha, M. J. Kujawa et al., “Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder,” Archives of General Psychiatry, vol. 60, no. 7, pp. 681–690, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. H. I. Kaplan and B. J. Sadock, Synopsis of Psychiatry, Williams & Wilkins, Baltimore, Md, USA, 8th edition, 1998.
42. E. Frank, D. J. Kupfer, C. M. Bulik, and J. A. Levenson, “Imipramine and weight gain during the treatment of recurrent depression,” Journal of Affective Disorders, vol. 20, no. 3, pp. 165–172, 1990. View at Publisher · View at Google Scholar · View at Scopus
43. J. B. Prince, T. E. Wilens, J. Biederman et al., “A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder,” Journal of Child and Adolescent Psychopharmacology, vol. 10, no. 3, pp. 193–204, 2000. View at Scopus
44. C. F. Paradis, J. A. Stack, C. J. George et al., “Nortriptyline and weight change in depressed patients over 60,” Journal of Clinical Psychopharmacology, vol. 12, no. 4, pp. 246–250, 1992. View at Scopus
45. M. Trivedi and A. Rush, “A review of randomized controlled medication trials in major depression,” Biological Psychiatry, vol. 31, pp. 188–189, 1992.
46. G. Chouinard, “Bupropion and amitriptyline in the treatment of depressed patients,” Journal of Clinical Psychiatry, vol. 44, no. 5, pp. 121–129, 1983. View at Scopus
47. J. W. Anderson, F. L. Greenway, K. Fujioka, K. M. Gadde, J. McKenney, and P. M. O'Neil, “Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial,” Obesity Research, vol. 10, no. 7, pp. 633–641, 2002. View at Scopus
48. E. Leinonen, J. Skarstein, K. Behnke, H. Ågren, and J. Th. Helsdingen, “Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder,” International Clinical Psychopharmacology, vol. 14, no. 6, pp. 329–337, 1999. View at Publisher · View at Google Scholar
49. D. Michelson, J. D. Amsterdam, F. M. Quitkin et al., “Changes in weight during a 1-year trial of fluoxetine,” American Journal of Psychiatry, vol. 156, no. 8, pp. 1170–1176, 1999. View at Scopus
50. C. D. Bouwer and B. H. Harvey, “Phasic craving for carbohydrate observed with citalopram,” International Clinical Psychopharmacology, vol. 11, no. 4, pp. 273–278, 1996. View at Scopus
51. C. A. Abell, D. L. Farquhar, S. M. Galloway, F. Steven, A. E. Philip, and J. F. Munro, “Placebo controlled double-blind trial of fluvoxamine maleate in the obese,” Journal of Psychosomatic Research, vol. 30, no. 2, pp. 143–146, 1986.
52. C. A. L. Moon and D. K. Jesinger, “The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice,” British Journal of Clinical Practice, vol. 45, no. 4, pp. 259–262, 1991.
53. M. Tohen, R. W. Baker, L. L. Altshuler et al., “Olanzapine versus divalproex in the treatment of acute mania,” American Journal of Psychiatry, vol. 159, no. 6, pp. 1011–1017, 2002. View at Publisher · View at Google Scholar · View at Scopus
54. B. H. Harvey and C. D. Bouwer, “Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors,” Clinical Neuropharmacology, vol. 23, no. 2, pp. 90–97, 2000. View at Publisher · View at Google Scholar · View at Scopus
55. L. Ribeiro, J. V. Busnello, M. Kauer-Sant'Anna et al., “Mirtazapine versus fluoxetine in the treatment of panic disorder,” Brazilian Journal of Medical and Biological Research, vol. 34, no. 10, pp. 1303–1307, 2001. View at Scopus
56. O. Benkert, A. Szegedi, and R. Kohnen, “Mirtazapine compared with paroxetine in major depression,” Journal of Clinical Psychiatry, vol. 61, no. 9, pp. 656–663, 2000. View at Scopus
57. E. Stip and V. Tourjman, “Aripiprazole in schizophrenia and schizoaffective disorder: a review,” Clinical Therapeutics, vol. 32, no. 1, pp. S3–S20, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. T. A. Pigott, A. Prakash, L. M. Arnold, S. T. Aaronson, C. H. Mallinckrodt, and M. M. Wohlreich, “Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder,” Current Medical Research and Opinion, vol. 23, no. 6, pp. 1303–1318, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. K. N. R. Chengappa, L. Chalasani, J. S. Brar, H. Parepally, P. Houck, and J. Levine, “Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review,” Clinical Therapeutics, vol. 24, no. 10, pp. 1576–1584, 2002. View at Publisher · View at Google Scholar · View at Scopus
60. V. Biton, W. Mirza, G. Montouris, A. Vuong, A. E. Hammer, and P. S. Barrett, “Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy,” Neurology, vol. 56, no. 2, pp. 172–177, 2001. View at Scopus
61. Ginsberg, et al., in Proceedings of the 156th Annual Meeting of the American Psychiatric Association, San Francisco, Calif, USA, May 2003.
62. Y. Lampl, Y. Eshel, A. Rapaport, and I. Sarova-Pinhas, “Weight gain, increased appetite, and excessive food intake induced by carbamazepine,” Clinical Neuropharmacology, vol. 14, no. 3, pp. 251–255, 1991. View at Scopus
63. G. Luef, I. Abraham, M. Haslinger et al., “Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women,” Journal of Neurology, vol. 249, no. 7, pp. 835–841, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. T. Baptista, L. Teneud, Q. Contreras et al., “Lithium and body weight gain,” Pharmacopsychiatry, vol. 28, no. 2, pp. 35–44, 1995. View at Scopus
65. D. Gothelf, B. Falk, P. Singer et al., “Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine,” American Journal of Psychiatry, vol. 159, no. 6, pp. 1055–1057, 2002. View at Publisher · View at Google Scholar · View at Scopus
66. D. B. Allison and D. E. Casey, “Antipsychotic-induced weight gain: a review of the literature,” Journal of Clinical Psychiatry, vol. 62, no. 7, pp. 22–31, 2001. View at Scopus
67. T. Kobayashi, K. Ikeda, and T. Kumanishi, “Effects of clozapine on the δ- and κ-opioid receptors and the G-protein-activated K+ (GIRK) channel expressed in Xenopus oocytes,” British Journal of Pharmacology, vol. 123, no. 3, pp. 421–426, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. G. Curzon, E. L. Gibson, and A. O. Oluyomi, “Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability,” Trends in Pharmacological Sciences, vol. 18, no. 1, pp. 21–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
69. A. D. Strosberg and F. Pietri-Rouxel, “Function and regulation of the β3-adrenoceptor,” Trends in Pharmacological Sciences, vol. 17, no. 10, pp. 373–381, 1996. View at Scopus
70. G. M. Goodwin, “How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs,” Journal of Clinical Psychiatry, vol. 57, no. 4, pp. 9–13, 1996. View at Scopus
71. S. H. Stahl, Essential Psychopharmacology, Cambridge University Press, New York, NY, USA, 1996.
72. N. G. Clark, “Consensus development conference on antipsychotic drugs and obesity and diabetes,” Diabetes Care, vol. 27, no. 2, pp. 596–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
73. D. Weiss, “How to help your patients lose weight: current therapy for obesity,” Cleveland Clinic Journal of Medicine, vol. 67, no. 10, pp. 739–754, 2000. View at Scopus
74. P. R. Thomas, Ed., Weighing the Options: Criteria for Evaluating Weight Management Programs, National Academy Press, Washington, DC, USA, 1995.
75. S. M. Hannum, L. Carson, E. M. Evans et al., “Use of portion-controlled entrees enhances weight loss in women,” Obesity Research, vol. 12, no. 3, pp. 538–546, 2004. View at Scopus
76. D. Umbricht, H. Flury, and R. Bridler, “Cognitive behavior therapy for weight gain,” American Journal of Psychiatry, vol. 158, no. 6, pp. 971–972, 2001. View at Publisher · View at Google Scholar · View at Scopus
77. H. M. Connolly, J. L. Crary, M. D. McGoon et al., “Valvular heart disease associated with fenfluramine phentermine,” New England Journal of Medicine, vol. 337, no. 9, pp. 581–588, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
78. K. P. Kelly and D. S. Kirschenbaum, “Immersion treatment of childhood and adolescent obesity: the first review of a promising intervention,” Obesity Reviews, vol. 12, no. 1, pp. 37–49, 2011.
79. M. Q. Werrij, A. Jansen, S. Mulkens, H. J. Elgersma, A. J. H. A. Ament, and H. J. Hospers, “Adding cognitive therapy to dietetic treatment is associated with less relapse in obesity,” Journal of Psychosomatic Research, vol. 67, no. 4, pp. 315–324, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
80. R. B. Saper, D. M. Eisenberg, and R. S. Phillips, “Common dietary supplements for weight loss,” American Family Physician, vol. 70, no. 9, pp. 1731–1738, 2004. View at Scopus
81. M. H. Pittler and E. Ernst, “Dietary supplements for body-weight reduction: a systematic review,” American Journal of Clinical Nutrition, vol. 79, no. 4, pp. 529–536, 2004. View at Scopus
82. J. R. T. Davidson, K. Abraham, K. M. Connor, and M. N. McLeod, “Effectiveness of chromium in atypical depression: a placebo-controlled trial,” Biological Psychiatry, vol. 53, no. 3, pp. 261–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
83. J. P. Docherty, D. A. Sack, M. Roffman, M. Finch, and J. R. Komorowski, “A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving,” Journal of Psychiatric Practice, vol. 11, no. 5, pp. 302–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
84. G. A. Bray, “Use and abuse of appetite-suppressant drugs in the treatment of obesity,” Annals of Internal Medicine, vol. 119, no. 7, pp. 707–713, 1993. View at Scopus
85. D. C. Klonoff and F. Greenway, “Drugs in the pipeline for the obesity market,” Journal of Diabetes Science and Technology, vol. 2, no. 5, pp. 913–918, 2008.
86. J. C. G. Halford, E. J. Boyland, J. E. Blundell, T. C. Kirkham, and J. A. Harrold, “Pharmacological management of appetite expression in obesity,” Nature Reviews Endocrinology, vol. 6, no. 5, pp. 255–269, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
87. L. M. Kaplan, “Pharmacologic therapies for obesity,” Gastroenterology Clinics of North America, vol. 39, no. 1, pp. 69–79, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
88. L. J. Aronne, A. E. Halseth, C. M. Burns, S. Miller, and L. Z. Shen, “Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial,” Obesity, vol. 18, no. 9, pp. 1739–1746, 2010. View at Publisher · View at Google Scholar · View at PubMed
89. G. A. Bray, D. H. Ryan, D. Gordon, S. Heidingsfelder, F. Cerise, and K. Wilson, “A double-blind randomized placebo-controlled trial of sibutramine,” Obesity Research, vol. 4, no. 3, pp. 263–270, 1996. View at Scopus
90. M. E. J. Lean, “Sibutramine—a review of clinical efficacy,” International Journal of Obesity, vol. 21, no. 1, pp. S30–S36, 1997. View at Scopus
91. M. Weintraub, A. Rubio, A. Golik, L. Byrne, and M. L. Scheinbaum, “Sibutramine in weight control: a dose-ranging, efficacy study,” Clinical Pharmacology and Therapeutics, vol. 50, no. 3, pp. 330–337, 1991. View at Scopus
92. M. J. Stock, “Sibutramine: a review of the pharmacology of a novel anti-obesity agent,” International Journal of Obesity, vol. 21, supplement 1, pp. S25–S29, 1997.
93. R. Guerciolini, “Mode of action of orlistat,” International Journal of Obesity, vol. 21, supplement 3, pp. S12–S23, 1997.
94. L. F. van Gaal, J. I. Broom, G. Enzi, and H. Toplak, “Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study,” European Journal of Clinical Pharmacology, vol. 54, no. 2, pp. 125–132, 1998. View at Publisher · View at Google Scholar · View at Scopus
95. L. Sjöström, A. Rissanen, T. Andersen et al., “Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients,” Lancet, vol. 352, no. 9123, pp. 167–172, 1998. View at Publisher · View at Google Scholar · View at Scopus
96. W. McNeely, P. Benfield, L. Drent, and F. X. Pi-Sunyer, “Orlistat,” Drugs, vol. 56, no. 2, pp. 241–250, 1998. View at Scopus
97. P. A. Hollander, S. C. Elbein, I. B. Hirsch et al., “Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study,” Diabetes Care, vol. 21, no. 8, pp. 1288–1294, 1998. View at Publisher · View at Google Scholar · View at Scopus
98. J. Zhi, A. T. Melia, S. G. Koss-Twardy, S. Arora, and I. H. Patel, “The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers,” Journal of Clinical Pharmacology, vol. 36, no. 2, pp. 152–159, 1996. View at Scopus
99. A. T. Melia, S. G. Koss-Twardy, and J. Zhi, “The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers,” Journal of Clinical Pharmacology, vol. 36, no. 7, pp. 647–653, 1996. View at Scopus
100. T. L. Schwartz and M. Beale, “Psychotropic induced weight gain alleviated with orlistat,” Psychopharm Bulletin, vol. 37, no. 1, pp. 5–8, 2003.
101. M. Floris, J. Lejeune, and W. Deberdt, “Effect of amantadine on weight gain during olanzapine treatment,” European Neuropsychopharmacology, vol. 11, no. 2, pp. 181–182, 2001. View at Publisher · View at Google Scholar · View at Scopus
102. A. Breier, Y. Tanaka, and S. Roychowdhury, “Nizatidine for the prevention of weight gain during olanzapine treatment in schizophrenia and related disorders: a randomised controlled double-blind study,” in Proceedings of the Meeting of the Colleges of Psychiatric and Neurologic Pharmacists, San Antonio, Tex, USA, March 2001.
103. M. C. Lessig, N. A. Shapira, and T. K. Murphy, “Topiramate for reversing atypical antipsychotic weight gain,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 40, no. 12, article 1364, 2001.
104. S. N. Ghaemi, S. G. Manwani, J. J. Katzow, J. Y. Ko, and F. K. Goodwin, “Topiramate treatment of bipolar spectrum disorders: a retrospective chart review,” Annals of Clinical Psychiatry, vol. 13, no. 4, pp. 185–189, 2001. View at Publisher · View at Google Scholar
105. E. Vieta, C. Torrent, G. Garcia-Ribas et al., “Use of topiramate in treatment-resistant bipolar spectrum disorders,” Journal of Clinical Psychopharmacology, vol. 22, no. 4, pp. 431–435, 2002. View at Publisher · View at Google Scholar
106. L. K. Ellinger, H. J. Ipema, and J. M. Stachnik, “Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain,” Annals of Pharmacotherapy, vol. 44, no. 4, pp. 668–679, 2010. View at Publisher · View at Google Scholar · View at PubMed
107. J. A. Morrison, E. M. Cottingham, and B. A. Barton, “Metformin for weight loss in pediatric patients taking psychotropic drugs,” American Journal of Psychiatry, vol. 159, no. 4, pp. 655–657, 2002. View at Publisher · View at Google Scholar
108. D. J. Klein, E. M. Cottingham, M. Sorter, B. A. Barton, and J. A. Morrison, “A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents,” American Journal of Psychiatry, vol. 163, no. 12, pp. 2072–2079, 2006. View at Publisher · View at Google Scholar · View at PubMed
109. H. A. Nasrallah, J. M. Meyer, D. C. Goff et al., “Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline,” Schizophrenia Research, vol. 86, no. 1–3, pp. 15–22, 2006. View at Publisher · View at Google Scholar · View at PubMed